Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Renalytix plcRNLX · Entity 7446 | President | July 10, 2023 | July 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Renalytix plc
Report date July 10, 2023 · Filed July 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Expires 2033-07-09 | Direct | 200,000 |
Reported balance
After 2023-07-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-10 · Grant · Acquired 200,000 · Balance 200,000 F1: The exercise price is 1.175 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.506 using the Bank of England rate as of July 10, 2023 (1.00 pound sterling = $1.282). F2: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 10, 2023, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is 1.175 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.506 using the Bank of England rate as of July 10, 2023 (1.00 pound sterling = $1.282).
F2: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 10, 2023, subject to the Reporting Person's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2023 Filed Jul 11, 2023 20:49 UTC | Renalytix plc RNLX · Entity 7446 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042021 · doc4.xml · derivative · entry 1 MCLAIN THOMAS H · CIK 0001206465 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2033-07-09 F1 · derivative.exercise_price: The exercise price is 1.175 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.506 using the Bank of England rate as of July 10, 2023 (1.00 pound sterling = $1.282). F2 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 10, 2023, subject to the Reporting Person's continuous service. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 20:26 UTC | Renalytix plc RNLX · Entity 7446 | GrantEmployee Stock Option (right to buy) · Derivative | 394,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041797 · doc4.xml · derivative · entry 1 MCLAIN THOMAS H · CIK 0001206465 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,486 Underlying: Ordinary Shares · 394,486 shares Expires 2033-07-05 F1 · derivative.exercise_price: The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269). F2 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 6, 2023, subject to the Reporting Person's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.